Expert Review of Cardiovascular Therapy最新文献_第8页

Adverse events and drug-drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure. 心力衰竭患者中钠-葡萄糖共转运蛋白2抑制剂的不良事件和药物相互作用。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-10 DOI: 10.1080/14779072.2023.2273900

Claudia Stöllberger, Josef Finsterer, Birke Schneider

{"title":"Adverse events and drug-drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure.","authors":"Claudia Stöllberger, Josef Finsterer, Birke Schneider","doi":"10.1080/14779072.2023.2273900","DOIUrl":"10.1080/14779072.2023.2273900","url":null,"abstract":"Introduction: Sodium glucose co-transporter 2-inhibitors (SGLT2-I), antihyperglycemic agents, are increasingly prescribed in chronic heart failure (CHF). Their risk for drug-drug interactions (DDI) seems low. Safety-data derive mainly from diabetes-patients. This review aims to summarize adverse-events (AE) and DDI of the SGLT2-I dapagliflozin, empagliflozin and sotagliflozin in patients with CHF.Areas covered: Literature-search-terms in PubMed were 'adverse event/drug-drug interaction' and 'heart failure AND 'dapagliflozin' OR 'empagliflozin' OR 'sotagliflozin.'AEreported in randomized controlled trials (RCT) comprisegenitaland urinary-tract infections, hypotension, ketoacidosis, renal impairment, hypoglycemia, limb-amputations, Fournier's gangrene, bone-fractures, hepatopathy, pancreatitis, diarrhea, malignancy and venous thromboembolism. Their incidence is largely unknown, since they were not consistently evaluated in RCT of CHF. Further AE from meta-analyses, pharmacovigilance reports, case-series and case-reports include erythrocytosis, hypertriglyceridemia, myopathy, sarcopenia, skin problems, ventricular tachycardia, and urinary retention. The maximal observation period of RCT in CHF was 26 months.DDI were mainly studied in healthy volunteers for 3-8 days. In CHF or diabetes-patients, DDI were reported with interleukin-17-inhibitors, linezolid, lithium, tacrolimus, valproate, angiotensin-receptor-neprilysin-inhibitors and intravenous iron.Expert opinion: Guidelines recommend treatment with SGLT2-I for CHF but no data on AE during long-term therapy and only little information on DDI are available, which stresses the need for further research. Evidence-based recommendations for ketoacidosis-prevention are desirable.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"803-816"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49675964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalized biomechanical insights in atrial fibrillation: opportunities & challenges. 房颤的个性化生物力学见解:机遇与挑战。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-10 DOI: 10.1080/14779072.2023.2273896

Åshild Telle, Clarissa Bargellini, Yaacoub Chahine, Juan C Del Álamo, Nazem Akoum, Patrick M Boyle

{"title":"Personalized biomechanical insights in atrial fibrillation: opportunities & challenges.","authors":"Åshild Telle, Clarissa Bargellini, Yaacoub Chahine, Juan C Del Álamo, Nazem Akoum, Patrick M Boyle","doi":"10.1080/14779072.2023.2273896","DOIUrl":"10.1080/14779072.2023.2273896","url":null,"abstract":"Introduction: Atrial fibrillation (AF) is an increasingly prevalent and significant worldwide health problem. Manifested as an irregular atrial electrophysiological activation, it is associated with many serious health complications. AF affects the biomechanical function of the heart as contraction follows the electrical activation, subsequently leading to reduced blood flow. The underlying mechanisms behind AF are not fully understood, but it is known that AF is highly correlated with the presence of atrial fibrosis, and with a manifold increase in risk of stroke.Areas covered: In this review, we focus on biomechanical aspects in atrial fibrillation, current and emerging use of clinical images, and personalized computational models. We also discuss how these can be used to provide patient-specific care.Expert opinion: Understanding the connection betweenatrial fibrillation and atrial remodeling might lead to valuable understanding of stroke and heart failure pathophysiology. Established and emerging imaging modalities can bring us closer to this understanding, especially with continued advancements in processing accuracy, reproducibility, and clinical relevance of the associated technologies. Computational models of cardiac electromechanics can be used to glean additional insights on the roles of AF and remodeling in heart function.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"817-837"},"PeriodicalIF":1.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10841537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50157467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis of cardiac sarcoidosis: histological evidence vs. imaging. 心脏结节病的诊断：组织学证据与影像学。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.1080/14779072.2023.2266367

Shinichi Kurashima, Takeshi Kitai, Andrew Xanthopoulos, John Skoularigis, Filippos Triposkiadis, Chisato Izumi

{"title":"Diagnosis of cardiac sarcoidosis: histological evidence vs. imaging.","authors":"Shinichi Kurashima, Takeshi Kitai, Andrew Xanthopoulos, John Skoularigis, Filippos Triposkiadis, Chisato Izumi","doi":"10.1080/14779072.2023.2266367","DOIUrl":"10.1080/14779072.2023.2266367","url":null,"abstract":"Introduction: The prognosis for cardiac sarcoidosis (CS) remains unfavorable. Although early and accurate diagnosis is crucial, the low detection rate of endomyocardial biopsy makes accurate diagnosis challenging.Areas covered: The Heart Rhythm Society (HRS) consensus statement and the Japanese Circulation Society (JCS) guidelines are two major diagnostic criteria for the diagnosis of CS. While the requirement of positive histology for the diagnosis in the HRS criteria can result in overlooked cases, the JCS guidelines advocate for a group of 'clinical' diagnoses based on advanced imaging, including cardiovascular magnetic resonance and 18F-fluorodeoxyglucose positron emission tomography, which do not require histological evidence. Recent studies have supported the usefulness of clinical diagnosis of CS. However, other evidence suggests that clinical CS may sometimes be inaccurate. This article describes the advantages and disadvantages of the current diagnostic criteria for CS, and typical imaging and clinical courses.Expert opinion: The diagnosis of clinical CS has been made possible by recent developments in multimodality imaging. However, it is still crucial to look for histological signs of sarcoidosis in other organs in addition to the endomyocardium. Additionally, phenotyping based on clinical manifestations such as heart failure, conduction abnormality or ventricular arrhythmia, and extracardiac abnormalities is clinically significant.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"693-702"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41112649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bivalirudin in acute coronary syndromes. 双缬氨酸治疗急性冠状动脉综合征。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-13 DOI: 10.1080/14779072.2023.2273902

Mattia Galli, Marco Bernardi, Luis Ortega-Paz, Roberto Nerla, Domenico D'Amario, Francesco Franchi, Giuseppe Biondi-Zoccai, Dominick J Angiolillo

{"title":"Bivalirudin in acute coronary syndromes.","authors":"Mattia Galli, Marco Bernardi, Luis Ortega-Paz, Roberto Nerla, Domenico D'Amario, Francesco Franchi, Giuseppe Biondi-Zoccai, Dominick J Angiolillo","doi":"10.1080/14779072.2023.2273902","DOIUrl":"10.1080/14779072.2023.2273902","url":null,"abstract":"Introduction: Bivalirudin, a bivalent direct thrombin inhibitor, has been developed to reduce bleeding without any trade-off in thrombotic events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).Areas covered: Despite showing a superior safety profile compared with unfractionated heparin (UFH), bivalirudin is not considered the anticoagulant of choice in ACS patients undergoing PCI, mainly because of an increased rate of acute stent thrombosis (ST) shown by several randomized controlled trials (RCTs), in addition to limited availability in certain countries and increased costs. However, RCTs on bivalirudin have been characterized by several confounding factors hindering the interpretation of its safety and efficacy compared with UFH among the spectrum of ACS patients. Furthermore, a significant body of evidence has demonstrated that the risk of acute ST can be mitigated by a full-dose infusion regimen following PCI, without compromising the favorable safety profile compared to UFH.Expert opinion: In light of the increased understanding of the prognostic relevance of bleeding events and the excellent safety profile of bivalirudin, recent trial evidence may allow for this anticoagulant agent to reemerge and have a more prominent role in the management of ACS patients undergoing PCI.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"901-911"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71421992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Genotype-guided dual antiplatelet therapy in cerebrovascular disease: assessing the risk and benefits for ethnic populations. 基因型引导的双抗血小板治疗脑血管疾病：评估种族人群的风险和益处。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-08-13 DOI: 10.1080/14779072.2023.2245754

Kasim Qureshi, Muhammad U Farooq, Philip B Gorelick

引用次数: 0

The use of digital health in heart rhythm care. 数字健康在心律护理中的应用。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-06-23 DOI: 10.1080/14779072.2023.2226868

Donald P Tchapmi, Chris Agyingi, Antoine Egbe, Gregory M Marcus, Jean Jacques Noubiap

{"title":"The use of digital health in heart rhythm care.","authors":"Donald P Tchapmi, Chris Agyingi, Antoine Egbe, Gregory M Marcus, Jean Jacques Noubiap","doi":"10.1080/14779072.2023.2226868","DOIUrl":"10.1080/14779072.2023.2226868","url":null,"abstract":"Introduction: Digital health is a broad term that includes telecommunication technologies to collect, share and manipulate health information to improve patient health and health care services. With the growing use of wearables, artificial intelligence, machine learning, and other novel technologies, digital health is particularly relevant to the field of cardiac arrhythmias, with roles pertinent to education, prevention, diagnosis, management, prognosis, and surveillance.Areas covered: This review summarizes information on the clinical use of digital health technology in arrhythmia care and discusses its opportunities and challenges.Expert opinion: Digital health has begun to play an essential role in arrhythmia care regarding diagnostics, long-term monitoring, patient education and shared decision making, management, medication adherence, and research. Despite remarkable advances, integrating digital health technologies into healthcare faces challenges, including patient usability, privacy, system interoperability, physician liability, analysis and incorporation of the huge amount of real-time information from wearables, and reimbursement. Successful implementation of digital health technologies requires clear objectives and deep changes to existing workflows and responsibilities.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":"21 8","pages":"553-563"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10306130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preventing atrial fibrillation in COVID-19: exploring the role of interleukin-6 receptor antagonists. 预防新冠肺炎心房颤动：探讨白细胞介素-6受体拮抗剂的作用。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.1080/14779072.2023.2264774

Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan

引用次数: 0

Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease. 监测冠状动脉疾病预后、疾病严重程度和治疗效果的生物标志物。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-10-26 DOI: 10.1080/14779072.2023.2264779

Armand N Yazdani, Michaela Pletsch, Abraham Chorbajian, David Zitser, Vikrant Rai, Devendra K Agrawal

{"title":"Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease.","authors":"Armand N Yazdani, Michaela Pletsch, Abraham Chorbajian, David Zitser, Vikrant Rai, Devendra K Agrawal","doi":"10.1080/14779072.2023.2264779","DOIUrl":"10.1080/14779072.2023.2264779","url":null,"abstract":"Introduction: Coronary Artery Disease (CAD) is a prevalent condition characterized by the presence of atherosclerotic plaques in the coronary arteries of the heart. The global burden of CAD has increased significantly over the years, resulting in millions of deaths annually and making it the leading health-care expenditure and cause of mortality in developed countries. The lack of cost-effective strategies for monitoring the prognosis of CAD warrants a pressing need for accurate and efficient markers to assess disease severity and progression for both reducing health-care costs and improving patient outcomes.Area covered: To effectively monitor CAD, prognostic biomarkers and imaging techniques play a vital role in risk-stratified patients during acute treatment and over time. However, with over 1,000 potential markers of interest, it is crucial to identify the key markers with substantial utility in monitoring CAD progression and evaluating therapeutic interventions. This review focuses on identifying and highlighting the most relevant markers for monitoring CAD prognosis and disease severity. We searched for relevant literature using PubMed and Google Scholar.Expert opinion: By utilizing the markers discussed, health-care providers can improve patient care, optimize treatment plans, and ultimately reduce health-care costs associated with CAD management.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"675-692"},"PeriodicalIF":1.8,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41115171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of anticoagulation therapy on kidney function in patients with atrial fibrillation and chronic kidney disease. 抗凝治疗对心房颤动和慢性肾脏疾病患者肾功能的影响。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 Epub Date: 2023-12-13 DOI: 10.1080/14779072.2023.2270909

Jelena Simic, Miroslav Mihajlovic, Nevena Zec, Vladan Kovacevic, Milan Marinkovic, Nebojsa Mujovic, Tatjana Potpara

{"title":"The impact of anticoagulation therapy on kidney function in patients with atrial fibrillation and chronic kidney disease.","authors":"Jelena Simic, Miroslav Mihajlovic, Nevena Zec, Vladan Kovacevic, Milan Marinkovic, Nebojsa Mujovic, Tatjana Potpara","doi":"10.1080/14779072.2023.2270909","DOIUrl":"10.1080/14779072.2023.2270909","url":null,"abstract":"Introduction: Atrial fibrillation (AF) and chronic kidney disease (CKD) are closely related. These diseases share common risk factors and are associated with increased risk of thromboembolic events. Choosing the appropriate oral anticoagulant therapy (OAC) in patients with AF and CKD is challenging. Deterioration of renal function is common in patients with AF treated with OACs, although not all OACs affect the kidneys equally.Areas covered: In this review, we aim to summarize the current knowledge of the prevention of thromboembolic events in patients with AF and CKD, focusing on the impact of specific OAC agents on renal function.Expert opinion: Consideration of OAC use is mandatory in patients with AF and CKD who are at increased risk of stroke or systemic embolism. Available evidence suggests that the use of non-vitamin K antagonist oral anticoagulants (NOACs) is associated with slower deterioration of renal function in comparison to Vitamin K antagonists (VKAs). Hence, a NOAC should be used in preference to VKAs in all NOAC-eligible patients with AF and CKD. Regarding patients with end-stage renal dysfunction and those on dialysis or renal replacement therapy, the use of NOAC should be considered in line with locally relevant formal recommendations.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"937-945"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41233597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathophysiology and management of saphenous vein graft disease. 大隐静脉移植物疾病的病理生理学和治疗。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2023-07-01 DOI: 10.1080/14779072.2023.2233420

Elizabeth C Ghandakly, Aaron E Tipton, Faisal G Bakaeen

{"title":"Pathophysiology and management of saphenous vein graft disease.","authors":"Elizabeth C Ghandakly, Aaron E Tipton, Faisal G Bakaeen","doi":"10.1080/14779072.2023.2233420","DOIUrl":"10.1080/14779072.2023.2233420","url":null,"abstract":"Introduction: The saphenous vein graft (SVG) is the most used conduit in CABG. With standardization of its use as a conduit came an understanding of its accelerated atherosclerosis, known as saphenous vein graft disease (SVGD). Given its extensive use, a review of the pathophysiology and management of SVGD is important as we optimize its use.Areas covered: For this review, an extensive literature search was completed to identify and examine the evolution of SVG in CABG, mechanisms driving SVGD, and methods developed to prevent and manage it. This includes a review of relevant major papers and trials in this space.Expert opinion: Eras of evolution in SVG usage in CABG include an experimental era, era of SVG dominance in CABG, and the current era of mixed venous and arterial grafting. As SVGD was studied, the mechanisms behind it became more understood, and prevention and management methods were developed. As advances in surgical techniques and pharmacotherapy continue to reduce occurrence and severity of SVGD, long-term patency of SV grafts continues to improve and remain excellent in optimized settings. With continued innovation and improvement in operative techniques, the SVG conduit is and will remain an important player in the field of coronary bypass.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":"21 8","pages":"565-572"},"PeriodicalIF":2.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10309377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1